What is the recommended starting dose and administration schedule of captopril for a 6‑kg infant, and what monitoring is required?

Captopril Dosing for a 6-kg Infant

For a 6-kg infant, start captopril at 0.3–0.5 mg/kg per dose (1.8–3 mg per dose) given three times daily (TID), administered one hour before meals. 1

Starting Dose Calculation

Based on the 2011 AAP pediatric cardiovascular guidelines, the initial captopril dose for infants ≥12 months is 0.3–0.5 mg/kg per dose 1. For your 6-kg infant:

• Initial dose: 1.8–3 mg per dose
• Frequency: Three times daily (TID)
• Timing: One hour before meals 2

The FDA labeling confirms this TID dosing schedule and emphasizes pre-meal administration to optimize absorption 2.

Dose Titration

The maximum dose is 6 mg/kg per day (36 mg/day for a 6-kg infant), divided into three doses 1. However, research in infants with congestive heart failure suggests:

• Start at the lower end of the dosing range (0.3 mg/kg/dose)
• Titrate slowly over 3–33 days to avoid hypotension 3
• Target maintenance doses typically range from 0.3–1.5 mg/kg/day in children 4

Formulation Considerations

Captopril is available as:

• Tablets: 12.5 mg, 25 mg, 50 mg (can be crushed)
• Oral suspension: 6 mg/mL concentration (commercially available or compounded by pharmacy) 1

For a 6-kg infant requiring 1.8–3 mg per dose, use 0.3–0.5 mL of the 6 mg/mL suspension per dose. Note that unlicensed liquid formulations show significant bioavailability variability and are not bioequivalent to tablets or to each other 5, so avoid switching formulations once therapy is established.

Critical Monitoring Requirements

Before Starting Therapy

• Baseline serum creatinine and potassium 1
• Blood pressure measurement 3
• Renal function assessment (especially important in smaller/premature infants) 3

During Therapy

Monitor closely for the first 5 days after initiation or dose increases, as most adverse effects occur during this period 3, 4:

1. Blood pressure: Check 1 hour after first dose, then regularly

   • Watch for excessive hypotension (>40% decrease from baseline) 6
   • Hypotension may persist 17±6 hours and be unresponsive to volume expansion 6

2. Renal function: Check serum creatinine and potassium

   • Renal impairment typically develops within 9 days of reaching final dose 3
   • Occurs more frequently in smaller infants (average 500g lighter) 3
   • Usually reversible with dose reduction or cessation 7, 3

3. Urine output: Monitor for oliguria (<1 mL/kg/hr)

   • May accompany severe hypotensive episodes 6

4. Clinical signs: Watch for lethargy, apnea, or subtle seizures

   • May develop 18±6 hours after oliguria onset 6

High-Risk Populations Requiring Extra Caution

Premature or low-birth-weight infants are at significantly higher risk for:

• Renal failure 7, 3, 6
• Unpredictable severe hypotension 6
• Prolonged oliguria 6

For these patients, consider starting at the absolute lowest dose (0.3 mg/kg/dose or even lower at 0.1 mg/kg/dose) with more intensive monitoring 7.

Common Pitfalls to Avoid

1. Do not start at adult-equivalent doses – infants require weight-based dosing with careful titration
2. Do not assume dose-related side effects – adverse events in infants are often unpredictable and not dose-dependent 3
3. Do not switch liquid formulations without increased monitoring – they are not bioequivalent 5
4. Do not skip pre-meal timing – absorption is optimized when given one hour before meals 2
5. Do not delay monitoring – most serious complications occur within the first week 3, 4

Contraindications and Precautions

• Contraindicated in pregnancy (though not relevant for infants, important for caregivers of childbearing age) 1
• Use with extreme caution in infants with:
  • Pre-existing renal impairment
  • Congenital heart disease with large left-to-right shunts 7
  • Volume depletion or concurrent diuretic therapy 2

All adverse effects are typically fully reversible with dose reduction or drug cessation 3, but close monitoring allows early detection and intervention before serious complications develop.